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Nanoparticles are being widely explored as potential therapeutics for numerous applications in medicine and have been shown
to signiﬁcantly improve the circulation, biodistribution, eﬃcacy, and safety proﬁles of multiple classes of drugs. One leading
class of nanoparticles involves the use of linear, cyclodextrin-containing polymers (CDPs). As is discussed in this paper, CDPs
can incorporate therapeutic payloads into nanoparticles via covalent attachment of prodrug/drug molecules to the polymer (the
basis of the Cyclosert platform) or by noncovalent inclusion of cationic CDPs to anionic, nucleic acid payloads (the basis of the
RONDEL platform). For each of these two approaches, we review the relevant molecular architecture and its rationale, discuss
the physicochemical and biological properties of these nanoparticles, and detail the progress of leading drug candidates for each
that have achieved clinical evaluation. Finally, we look ahead to potential future directions of investigation and product candidates
based upon this technology.
1.Cyclosert:RationaleandIntroduction
Ever since Paul Ehrlich introduced the concept of the “magic
bullet”—that is, the combination of an agent conferring
selectivity towards a disease-causing organism with a ther-
apeutic agent—scientists have worked towards achieving this
vision. One way to achieve selectivity towards certain disease
states was to develop a prodrug that would be administered
in its inactive and nontoxic form but would be metabolized
to its active form once it reached the diseased organ. Prodrug
approacheshavebeenusedbymedicinalchemiststoimprove
the absorption, distribution, metabolism, and excretion
(ADME) of many small-molecule drugs. This approach
was also important in increasing the selectivity of many
small-molecule drugs, especially in the ﬁeld of oncology.
Examples such as irinotecan (a prodrug of the camptothecin
analog, SN-38), capecitabine (a prodrug of 5-FU), and
etoposide phosphate (a prodrug of etoposide) have shown
clinical success and thereby demonstrated the value of this
approach. This concept was further expanded through the
development of macromolecular prodrugs. The rationale for
using macromolecules as drug carriers is that they may be
able to incorporate many more functional features than a
relatively simple small molecule, therefore enabling them
to perform complex functions at the right time and right
place within a patient. A nanoparticle drug, one form of a
large macromolecular drug, has a hydrodynamic diameter
between ∼10 and ∼100nm. Many types of nanoscaled
drugs, such as antibody conjugates, polymer conjugates, and
liposomal drugs, have been developed. The most important
functional features of nanoparticle drugs are shown in
Table 1.
Here, we discuss the preclinical and clinical development
of a class of nanoparticles for the delivery of small-molecule
drugs based on linear, cyclodextrin-based polymers (CDPs).
CDPs contain alternating repeat units of β-cyclodextrin
(CD) and polyethylene glycol (PEG) with two carboxylate
groups per repeat unit for drug conjugation (Figure 1).
Both components are commonly used in drug delivery
applications. Cyclodextrins are cyclical sugar molecules with
a hydrophilic exterior and hydrophobic cavity interior. High
aqueoussolubilityandtheabilitytoencapsulatehydrophobic
moieties within their cavity through the formation of
inclusion complexes enable cyclodextrins to enhance the2 Journal of Drug Delivery
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Figure 1: Structure of linear, cyclodextrin-based polymer (CDP) for small molecule delivery. The polymer consists of the cyclical sugar
β-cyclodextrin that has been difunctionalized with the natural amino acid cysteine (CDDCys) and polyethylene glycol (PEG). Two small-
molecule drugs per polymer repeat unit can be attached via various linker chemistries, resulting in a neutrally charged, highly water-soluble
polymer conjugate.
Table 1: Key nanoparticle characteristics and their eﬀect on in vivo
functionality.
Nanoparticle characteristics Function
Diameter between 10 and
100nm
Control over pharmacokinetics
and biodistribution
Surface properties (charge,
hydrophilicity)
Solubility, protection from
aggregation, and interaction with
cells and proteins
Core properties
Protection of payload from
chemical and enzymatic
inactivation, control of release
kinetics
Linker chemistry
Protection of drug from chemical
or enzymatic inactivation, control
of release kinetics
Targeting ligands Control of cell surface binding
and intracellular uptake
solubility, stability, and bioavailability of hydrophobic small-
molecule drugs [1]. PEG is often used in pharmaceutical
applications to increase the solubility, stability and plasma
half-life of drugs [2].
InordertoformtheCDPpolymers,adifunctionalizedβ-
cyclodextrin is reacted with a difunctionalized PEG through
condensation polymerization [3]. The resulting polymer
is highly water soluble and neutrally charged when fully
conjugated with drug through various linkers. This results
in a high biocompatibility of the polymer, eliciting no
observable side eﬀects or immune responses at intravenous
doses up to 240mg/kg in mice [4]. A number of small-
molecule drugs such as camptothecin [3], a natural alkaloid
antineoplastic agent, tubulysin [5], a naturally occurring
tetrapeptide with antineoplastic activity isolated fromstrains
of myxobacteria, and methylprednisolone [6], an steroid
anti-inﬂammatorydrug,havebeenattachedtoCDPthrough
v a r i o u sl i n k e r s( Table 2). One of the unique features of
CDP is that the CD blocks form inclusion complexes
with hydrophobic small-molecule drugs through both intra-
and intermolecular interactions. Such interactions between
adjacent polymer strands are essential for catalyzing the self-
assembly of several CD-PEG polymer strands into highly
reproducible nanoparticles (Figure 2). Parameters aﬀecting
the particle size are the type of drug, the polymer molecular
weight, and the drug loading. Covalent attachment of a
hydrophobic drug is required to initiate self-assembly, and
release of drug from the polymer results in the disassemblyJournal of Drug Delivery 3
50 nm
Figure 2: Transmission electron micrograph (TEM) of CRLX101
(from [8]).
into individual polymer strands of 8-9nm, which have the
potential to be cleared through the kidney [5–7].
CDP-based nanoparticles are highly water soluble at
concentrations >100mg/mL, limited by the high viscosity of
resulting solutions, increasing the solubility of hydrophobic
drugs by more than 100-fold (Table 2). One attractive
feature of nanoparticle prodrugs is their ability to protect
small-molecule therapeutics from enzymatic and chemical
degradation. This was impressively shown in the case of
the camptothecin (CPT) drug, CRLX101 (formerly IT-101).
The chemical structure of CPT includes an unstable lactone
ring that is highly susceptible to spontaneous and reversible
hydrolysis, which yields an inactive, but more water-soluble,
carboxylate form that predominates at physiologic pH. To
form CRLX101, CPT is derivatized at the 20-OH position
with the natural amino acid glycine to form an ester linkage
forcovalentattachmenttoCD-PEG(Table 2).In vitro studies
conﬁrmed that this linker strategy successfully stabilizes the
labile lactone ring of CPT in its closed, active form. Release
of CPT from the nanoparticles was found to be mediated
through both enzymatic and base-catalyzed hydrolyses of
the ester bond, with observed half-lives of 59 and 41 hours
in PBS and human plasma, respectively [3]. Release of
methylprednisolone showed similar kinetics, with observed
half-lives of 50 and 19 hours in PBS and human plasma,
respectively [6]. These release kinetics are substantially
slower than what is typically observed with nonnanoparticle
ester prodrugs [9, 10] and this is most likely due to the
displacement of water from within and reduced access of
enzymes to the hydrophobic core of CDP nanoparticles. The
disulﬁde linked ester conjugate was signiﬁcantly more stable,
with minimal release observed in PBS or human plasma over
72 hours [5].
The ability of any nanoparticle therapeutic to deliver the
payload to the target cell and release it at the right time and
location will be important for its performance. Release of the
payload can be triggered by various mechanisms, depending
on the linker chemistry. CDP polymers have been used in
combinationwithesterlinkages,suchasglycineortriglycine,
as well as disulﬁde linkers. While ester linkers are cleaved
through pH-dependent and enzymatic hydrolysis, disulﬁde
linkers are cleaved in response to a change in redox potential
upon intracellular uptake of the nanoparticle. In vitro and
in vivo studies showed that CDP nanoparticles are taken up
by various cell types, including tumor cells and cells of the
immune system [4, 7, 11]. Intracellular uptake and release
are also directly correlated to the in vitro potency of the
conjugate. In the case of CRLX101, the in vitro potency was
foundtobe betweenone-halftoone-tenththe potency ofthe
unconjugated CPT in a 48-hour MTS assay [12]. In contrast,
the in vitro potency for the disulﬁde-conjugated tubulysin
nanoparticlewassimilartothatforthefreedrugina48-hour
assay, consistent with a more rapid release after intracellular
uptake [5]. The time dependence of in vitro potency was
studied more extensively in the case of the ester-linked
methylprednisolone nanoparticle, for which the potency of
thenanoparticle at5daysinalymphocyteproliferationassay
was higher than that of free drug [6]. In the same assay, the
free drug was more potent at 3 days, consistent with the slow
release of active drug from the nanoparticle over time.
2.PharmacokineticsandPharmacodynamicsof
Cyclosert-Based Nanoparticle Drugs
The ability of nanoparticles to dramatically change the
pharmacokinetics (PK) and biodistribution of drugs on
both a macroscopic level (i.e., whole organ) and a micro-
scopic (i.e., cellular) level is key to achieving the desired
improvements in pharmacodynamics (PD) and, ultimately,
therapeutic index. Plasma PK after intravenous injection was
extensively studied for CRLX101 by traditional HPLC assays
inrats[13]andbymicro-PET/CTinmiceusing 64Cu-labeled
nanoparticles [7]. The nanoparticle PK is characterized by a
low volume of distribution approximately equal to the total
blood volume and long terminal half-life of 13 to 20 hours
in mice and rats, respectively. This result indicates that the
nanoparticles are able to avoid ﬁrst-pass kidney clearance,
which is commonly observed for drugs with hydrodynamic
diameters below 10nm [14]. This was in contrast to the PK
of CPT alone, which showed a high volume of distribution
and short terminal half-life of 1.3 hours.
After intravenous administration, CDP nanoparticles
therefore form a circulating reservoir of active drug that is
subsequently distributed to multiple organs. Consistently,
tumortissueshowedhighdrugconcentrations24to48hours
after injection of nanoparticles. Other tissues with high drug
concentrations were liver, spleen, and kidney, while most
other organs showed low concentrations. A detailed study
of multiorgan PK by PET/CT and histology revealed that
CRLX101 nanoparticles were taking advantage of the unique
tumor physiology characterized by a high density of abnor-
mal blood vessels, high vascular permeability, and decreased
rate of clearance due to a lack of lymphatic drainage, all of
whichacttogethertocauseaccumulation.Thisphenomenon
has also been called the enhanced permeability and retention
(EPR) eﬀect [15]. In the same study, intact nanoparticles
were found inside cancer cells distributed throughout the
tumor tissue, forming an intracellular reservoir of active4 Journal of Drug Delivery
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drug. This intracellular accumulation can also explain the
ﬁnding that tumoral concentrations of CRLX101 and re-
leased CPT remained relatively constant for several days
after intravenous injection, as opposed to the rapid decline
(over several orders of magnitude in less than 24 hours)
of irinotecan and its active metabolite, SN-38, in several
preclinical lymphoma models [16]. These increased tumor
concentrations also correlated with increased inhibition
of topoisomerase I enzymatic activity at 48 hours after
administration by CRLX101 compared to irinotecan.
Studies of the biodistribution and cellular uptake of
ﬂuorescently labeled CDP nanoparticles (NPs) in a syn-
geneic glioma model in C57BL/6 mice showed an addi-
tional mechanism of nanoparticle transport and distribution
[11]. Irrespective of route of administration (intravenous
versus intracranial), CDP-NPs were more eﬃciently taken
upbytumor-associatedmacrophages(TAMs),macrophages,
and microglia, than tumor cells. These TAMs not only
internalized NPs by phagocytosis but also were able to
migrate into the circulation after local intracranial CDP-
NPinjections.Additionally,NP-positiveTAMsdistributedto
distant tumors within the CNS after local intracranial deliv-
ery. One unique characteristic of the ﬂuorescently labeled
CDP-NPs used for these studies was their slightly positive
surface charge, while all of the other CDP-NPs discussed
here had a slightly negative to neutral surface charge. Taken
together, these observations indicate that CDP-NPs could
be tuned to circulate as free NPs in plasma for prolonged
periods of time and/or be taken up by immune cells such
as TAMs and transported via cell migration. Both of these
eﬀects may occur at the same time and are not mutually
exclusive.Inadditiontocancer,theseﬁndingsofmacrophage
transport may have implications for the application of CDP-
NPs in other indications, such as inﬂammatory diseases. It
is conceivable that some of the enhanced in vivo activity of
Cyclosert-methylprednisolone [6] was also due to immune
cell-mediated transport.
One major beneﬁt of these PK and PD improvements is
a dramatic increase in therapeutic index for many small-
molecule drugs. For example, CPT essentially has no
therapeutic window and its development was abandoned
due to excessive toxicity. CRLX101, in contrast, has shown
to be highly active in multiple human subcutaneous and
disseminatedcancermodels[16,17].Inallcasesstudied,one
treatment cycle of 3 weekly doses of CRLX101 resulted in
signiﬁcant antitumor activity that was superior to irinotecan
or topotecan, two small-molecule analogs of CPT. In the
case of tubulysin A (TubA), the increase in therapeutic index
was even more impressive, showing a >100-fold increase
in maximum tolerated dose (MTD). Whereas TubA at its
MTD was completely inactive, CDP-TubA showed equal or
superior eﬃcacy compared with vinblastine and paclitaxel
reference treatments with minimal observed toxicity [5].
While cancer is a natural indication for nanoparticle drugs,
many other indications may be amenable to treatment
with nanoparticle drugs. The common denominator in
these diseases is the presence of inﬂammation resulting in
similarphysiologicalchanges,suchasneovascularizationand
high vascular permeability. Preclinical studies in models of
Table 3: Nanoparticle-speciﬁc independent variables, process con-
trolmeasures,anddependentvariablesusedinsettingspeciﬁcations
for Cyclosert drugs.
Independent
variable
Process control
measures
Dependent
variable
Polymer molecular
weight and polydispersity
Real-time viscosity
determination during
polymerization
Particle size
Drug loading Stoichiometry of
coupling reaction
Particle size,
release kinetics
rheumatoid arthritis showed that this approach can work for
anti-inﬂammatory therapy and may be expanded to other
disease indications [6].
3. CRLX101 ClinicalTranslation
Based on the preclinical activity of CRLX101, clinical devel-
opment was initiated. This required a signiﬁcant investment
in process improvements and scale-up of nanoparticle
manufacturing. Speciﬁc process challenges that had to be
overcome were the control over the polymerization reaction,
consistency of drug loading, and reproducible nanoparticle
formation. In order to set appropriate speciﬁcations for
key parameters potentially aﬀecting the in vivo character-
istics of the drug, a bracketing approach was chosen. Key
nanoparticle speciﬁc parameters identiﬁed were polymer
molecular weight (Mw) and drug loading, both of which are
controllable by speciﬁc process control measures, as well as
the particle size, which is a function of the two independent
parameters (Table 3). A series of nanoparticle compounds
bracketing each independent parameter were synthesized,
their particle sizes determined, and pharmacokinetics and
pharmacodynamicsevaluatedinvivo.Resultsofthesestudies
were then used to set upper and lower speciﬁcation limits for
both independent and dependent variables.
A phase I study of CRLX101 in patients with refractory
solid tumors was initiated. The primary objectives of this
ﬁrst-in-man study were to determine the safety, pharma-
cokinetics, dose-limiting toxicities, and MTD, as well as the
recommended dose and dosing schedule for future studies.
Secondary objectives of the study included the assessment
of potential biomarkers, an estimation of clinical activity by
RECIST, and an estimation of progression-free survival in
patients receiving multiple cycles of CRLX101 monotherapy.
Interim results of that study are available [18].
Patients with refractory solid tumors received CRLX101
using either 3 weekly (Qwkx3) or every other week (Qow)
infusions every 28 days. CRLX101 was administered at 6,
12, or 18mg/m2 Qwkx3 and 12 or 15mg/m2 Qow. The
occurrence of adverse events during the ﬁrst cycle was
used to assess the toxicokinetics. As of the interim analysis,
eighteen patients had been enrolled; of these, 12 patients
received CRLX101 Qwkx3 and 6 Qow. Consistent with
preclinical results, CRLX101 showed a long elimination half-
life of 31.8 and 43.8 hours for polymer-bound and free
CPT, respectively. Volume of distribution of the polymer6 Journal of Drug Delivery
conjugate was 4.2 ± 1.1 liters, indicating that CRLX101 is
initially primarily retained in the vasculature. An analysis of
toxicokinetics in patients that received CRLX-101 either on
the Qwkx3 or Qow schedule showed that tolerability was
improved on the Qow regimen while maintaining similar
per-cycle drug exposures. Hematologic toxicity was dose
limiting at 18mg/m2 on the weekly schedule. The authors
concluded that CRLX101 given intravenously appeared safe
whenadministeredbetween18and30mg/m2/monthinboth
Qwkx3 and Qow regimens; however, the Qow schedule was
better tolerated. More recently [19], data from additional
patients dosed on the Qow regimen highlight observations
of stable disease in advanced non-small-cell lung carcinoma
(NSCLC) patients. Speciﬁcally, the interim data showed that
70% of the NSCLC patients achieved stable disease of greater
than or equal to 3 months, and 20% of them achieved stable
disease of greater than or equal to 6 months. Accrual of this
phase I study has since been completed, and a randomized
phase 2 study of CRLX101 in patients with advanced NSCLC
has been initiated. Results from these upcoming studies will
be critical for establishing the potential of CRLX101 as a new
oncology agent.
4. RONDEL: IntroductionandRationale
Thedevelopmentoflinearcyclodextrin-containingpolymers
(CDPs)fornucleicaciddeliverytracesbacktothemid-1990s
in the laboratory of Dr. Mark Davis at Caltech (Figure 3). In
order to function as delivery agents for polyanionic nucleic
acids, of which DNA oligonucleotides and plasmid DNA
(pDNA) were most prevalent at that time, cationic polymers
were conceived by Dr. Davis as those that would contain
several key attributes: (i) assemble with nucleic acids to yield
small (∼100nm or below in diameter) colloidal particles,
(ii) could be easily modiﬁed with a stabilizing agent (e.g.,
poly(ethylene glycol) (PEG)) and a targeting ligand to facili-
tate in vivo stability and engagement of cell surface receptors
on target cells and promote endocytosis, and (iii) respond
to vesicular acidiﬁcation as a trigger to escape the endosome
and trigger particle disassembly, thereby releasing the nucleic
acid payload within the cytoplasm. Cyclic oligomers of
glucose, cyclodextrins were selected as the foundation of
these polymers because of their known low toxicity, lack
of immunogenicity, and ability to form noncovalent guest-
host inclusion complexes with hydrophobic small molecules;
the ﬁrst description of the synthesis of a cationic CDP
and characterization of the nanoparticles it formed with
pDNA, including their in vitro transfection eﬃciency, was
published in 1999 [20]. To overcome the salt-induced
aggregation of CDP/pDNA nanoparticles in physiological
media, chemistry was developed to conjugate a neutral
stabilizing polymer, PEG, to a hydrophobic small molecule,
adamantane (AD), which forms strong inclusion complexes
with β-cyclodextrin. In this manner, nanoparticles could be
noncovalently stabilized, and this approach was extended to
allow incorporation of targeting ligands via preparation of
AD-PEG-ligand conjugates [21, 22]. Utilizing a small inter-
fering RNA (siRNA) targeting the EWS/Fli1 fusion oncogene
and the human transferrin protein as a targeting ligand, the
ﬁrst in vivo proof-of-concept experiments were performed
shortly thereafter in a disseminated murine model of Ewing’s
sarcoma [23]. The signiﬁcant antitumor eﬀect demonstrated
in this work motivated the creation of a company, Calando
Pharmaceuticals, to further advance this delivery platform
(RONDEL) towards therapeutic candidates suitable for
clinical evaluation in human cancer patients. The ﬁrst such
candidate, termed CALAA-01, contained an siRNA targeting
the M2 subunit of ribonucleotide reductase (RRM2), a pro-
tein involved in DNA replication whose function is required
to complete cell division. Upon identiﬁcation of the optimal
anti-RRM2 siRNA sequence [24] and evaluation of the in
vivo nanoparticle performance [25], an IND application was
submitted to the Food and Drug Administration (FDA)
and Calando received approval to initiate a phase I trial
of CALAA-01 in patients with solid tumors in 2008. In
2010, encouraging interim clinical data from this study was
published[26,27]whichrevealed,inadditiontoapromising
safety proﬁle and multiple dose escalations, the ﬁrst evidence
of the RNA interference (RNAi) mechanism of action in
humans and the ﬁrst dose-dependent tumor accumulation
in humans of nanoparticles of any kind upon systemic
administration.
In this paper, we describe the development of each of the
components of this nucleic acid delivery system. We review
the assembly of these nanoparticles, including their physic-
ochemical properties and in vivo performance. The devel-
opment of the CALAA-01 drug product is then discussed,
including selection of the gene target and siRNA sequence
optimization, safety and eﬃcacy evaluations in animals,
and manufacturing/scale-up of the components. The clinical
ﬁndings of CALAA-01 are then discussed, including char-
acterization of safety parameters (pharmacokinetics (PK),
complement activation, cytokine levels, serum chemistry,
complete blood counts (CBCs), and adverse events), and
eﬃcacyandadiscussionofexploratoryobjectives.Finally,we
conclude with a survey of additional explorations conducted
with this delivery platform with an eye towards next-
generation therapeutic candidates.
5. RONDEL Components
Fully formulated nanoparticles made with the RONDEL
(RNAi/Oligonucleotide Nanoparticle Delivery) system, such
as the CALAA-01 drug product developed by Calando
Pharmaceuticals currently in clinical evaluation, contain a
total of four (4) components described below.
The three primary cyclodextrins (CDs)—α, β,a n dγ—
are cyclic oligomers comprised of 6, 7, and 8 glucose
moieties, respectively. Functionalization and polymerization
eﬀortswereconductedwiththesecyclodextrinspeciesaspart
of several studies to assess structure-activity relationships
(SARs) of cationic polymers varying in properties such
as carbohydrate size, carbohydrate distance from charge
centers, and charge center type [28–31]. In general, the
cyclodextrins were difunctionalized and reacted with a
difunctionalcomonomertoyieldlinear,AB-typecopolymers
(Figure 4). A number of trends emerged from these SARJournal of Drug Delivery 7
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Figure 3: Timeline of the development of cyclodextrin-containing polymers (CDPs) for nucleic acid delivery.
studies(Table 4)whichledtotheidentiﬁcationofapreferred
structure for the CD-containing polymer (CDP) which was
the focus of further development (Figure 5). Designated as
“βCDP6,” “CDPim,” or “CAL101” in various publications
(hereafter referred to as CAL101), this polymer is made by
copolymerization of β-CD diamine and dimethylsuberimi-
date (which imparts two amidine charge centers separated
by six methylene units), and its termini are modiﬁed to
contain an imidazole derivative. This modiﬁcation has been
shown to facilitate enhanced transgene expression from a
plasmid DNA (pDNA) payload and to signiﬁcantly release
intracellularreleaseofsiRNA(Figure 6).Nanoparticlesmade
with CAL101 and pDNA yielded signiﬁcant gene delivery
in transfected cultured cells, comparable to that of leading
commercially available transfection reagents, with low cyto-
toxicity. Despite this in vitro potency, these charged colloidal
CAL101/nucleic acid nanoparticles rapidly aggregate in
physiological medium, rendering them unﬁt for in vivo
application; this phenomenon motivated investigation into
incorporation of a stabilizing agent.
The objectives of addition of a stabilizing agent to
CAL101-containing nanoparticles are to minimize self-self
(aggregation) and self-nonself (e.g., protein binding) inter-
actions in an animal or human subjects receiving a systemic
administration of these nanoparticles. For cancer treatment
in particular, it is known that passive targeting of nanopar-
ticles to tumors can occur through a prolonged circulation
time which enables extravasation through fenestrated tumor
neovasculature (enhanced permeation and retention (EPR)
eﬀect). Thus, in order to direct the biodistribution of
CAL101/nucleic acid nanoparticles such that tumor uptake
is maximized (and the potential for oﬀ-target deposition
and toxicities are minimized), eﬀorts to incorporate a
neutral polymer, PEG, to stabilize these nanoparticles were
undertaken.
While PEGylation of cationic polymer-based nanoparti-
cles to extend circulation times and prevent aggregation was
widely performed, it typically required covalent attachment
of PEG at the same polymer functional sites required for
nucleic acid binding. This tradeoﬀ is undesirable, and it was
overcome in this case due to exploitation of the β-CD moiety
within CAL101 (Figure 7). Forming strong noncovalent
inclusion complexes with β-CD (association constant of ∼
104-105M
−1), adamantane (AD) was conjugated to one
terminus of a linear PEG (AD-PEG) and added to CAL101
either before (pre-PEGylation) or after (post-PEGylation)8 Journal of Drug Delivery
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Table 4: Parameters and result summaries for early investigations of polymer structure-activity relationships (SARs).
Parameter Variants tested Results/trends Reference(s)
Carbohydrate size
(i) Trehalose
(ii) α-CD
(iii) β-CD
(iv) γ-CD
(v) (hexane)
(i) The absence of a carbohydrate produces
high toxicity and reduces water solubility
(ii) CD-containing species had comparable
properties
[29]
Carbohydrate distance
from charge centers
(spacer length) and
hydrophilicity of the
spacer
( i )4 ,5 ,6 ,7 ,a n d8v e r s u s1 0
methylene units
(ii) alkyl versus alkoxy spacers
(i) Transfection eﬃciency is dependent on
distance from charge centers, with up to
20-fold diﬀerence among β-CD-containing
polymers [28, 29, 31]
(ii) As the charge center is further removed
from the carbohydrate unit, the toxicity is
increased
(iii) Optimum transfection is achieved with
a spacer length of 6 methylene units
(iv) Increasing hydrophilicity of the spacer
(alkoxy versus alkyl) provides for lower
toxicity
Cyclodextrin
functionalization
(i) 6A,6 D-Dideoxy-6A,6 D-
Diamino-β-CD
(ii) 3A,3 D-Dideoxy-3A,3 D-
Diamino-β-CD
(iii) 3A,3 B-Dideoxy-3A,3 B-
Diamino-γ-CD
(i) The structure of diaminated CD
monomers was found to inﬂuence both the
molecular weight and polydispersity of
polycations resulting from reaction of these
compounds with dimethylsuberimidate
(DMS)
[31]
(ii) Longer alkyl regions in the polycation
backbone increased transfection eﬃciency
and toxicity, while increasing hydrophilicity
was toxicity reducing
(iii) γ-CD polycations were shown to be less
toxic than otherwise identical β-CD
polycations
Charge center type (i) Amidine
(ii) Quaternary ammonium
(i) Quaternary ammonium analogues
exhibit lower gene expression values and
similar toxicities to their amidine analogues
[30]
Termini
(i) Primary amine
(ii) Histidine
(iii) Imidazole
(i) Incorporation of pH-buﬀering moiety to
polymer termini increases gene delivery,
buﬀers acidiﬁcation experienced by
nanoparticles, and enhances intracellular
release of nucleic acid payload
[33–35]
CAL101 had been combined with the nucleic acid of
interest. In this manner, simple physical mixing of these
components was suﬃcient to achieve suﬃcient interaction
and incorporation of AD-PEG into the nanoparticles. A
minimum PEG length of 5kDa was shown to be required
to prevent salt-induced aggregation of these nanoparticles
[21], and thermodynamic analysis suggests that length-
dependent interactions among PEG chains on the surface
of nanoparticles contribute signiﬁcantly to the eﬀective
stabilization [36]. This AD-PEG5000 conjugate was the focus
of future development work for this RONDEL delivery
platform as well as clinical translation of the CALAA-01
therapeutic candidate.
HavingincludedCAL101asacondensingagenttoinduce
nanoparticle formation and AD-PEG as a stabilizing agent
to render these nanoparticles suitable for in vivo application,
a third component was investigated which would facilitate
cellular internalization of nanoparticles. Typical candidates
for such an agent in nanoparticle formulations are ligands
(in the form of peptides, proteins/antibodies, aptamers,
or small molecules) whose cognate receptor is expressed
on the surface of target cells either exclusively or to a
much greater extent than on other (nontarget) cells. For
application of these nanoparticles to cancer, the transferrin
receptor (TfR) was selected [22] as a target owing to its
signiﬁcant overexpression on a variety of cancer cell types
[37]; indeed, TfR is a well-studied surface protein for tar-
geting of cancer therapeutics [38, 39]. The aforementioned
AD/β-CD inclusion complex phenomenon was exploited to
incorporate the human transferrin (Tf) protein to these
nanoparticles. Speciﬁcally, Tf was conjugated to the distal
end of a functionalized AD-PEG5000 to yield an AD-PEG5000-
Tf species which could also contribute to nanoparticles via
physical mixing with the other components. Owing to the10 Journal of Drug Delivery
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Figure 6: Eﬀect of imidazole incorporation within CDP upon
gene delivery eﬃciency and intracellular siRNA release. (a) Incor-
poration of an imidazole derivative within CDP (CDPim) leads
to a signiﬁcant increase in transgene (luciferase) expression levels
in transfected HeLa and BHK-21 cells (from [33]). (b) Imidazole
incorporation (CDPimid) yields a signiﬁcant (∼4x) increase in the
fractionofintracellularsiRNAthatisreleasedfromthepolymerand
able to migrate through an agarose gel when electrophoresed (from
[34]).
signiﬁcant size (∼80kDa) and net anionic charge of Tf,
the range of stoichiometries which would retain desired
nanoparticles size and stability while yielding a biological
eﬀect was established (Figure 8). As is discussed below and
has been reviewed previously [40], the presence of AD-PEG-
Tfwithinthesenanoparticlesdoesnotsigniﬁcantlyaltertheir
overall biodistribution but appears to enhance activity in
vivo,presumablythroughenhancedinternalizationbycancer
cells.
The ﬁnal component of the nanoparticles, the siRNA,
is typically a canonical siRNA (two 21-nucleotide strands
sharing19ntofWatson-Crickcomplementaritywith2-nt,3 
overhangs) although successful formulation with alternative
RNAi constructs has been observed. Because protection
from serum nucleases is aﬀorded by formulation within
CAL101-containing nanoparticles, replacement of native
phosphodiester linkages with phosphorothioates (which
impart nuclease resistance) was not performed. In addition,
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Figure 7: Formation of inclusion complexes between adaman-
tane (AD) and β-cyclodextrin allows straightforward, noncovalent
incorporation of stabilizing (via PEG-AD conjugates) and/or tar-
geting (via ligand-PEG-AD conjugates) components to a polymer-
nucleic acid nanoparticles (polyplex) (Figure from [21]).
because preclinical investigation did not reveal evidence of
strongimmunogenicityattherapeuticallyrelevantdoselevels
(as discussed below), siRNA modiﬁcations that may reduce
cytokine activation via Toll-like receptor (TLR) interaction,
such as 2 -OMe and 2 -F, were not imposed. As a result,
the siRNA species investigated within these nanoparticles as
described in this paper are truly native/unmodiﬁed species
whose degradation products are naturally occurring and
require no special chemistries to synthesize.
ThemodularnatureofthesesiRNA-containing nanopar-
ticlesaﬀordsﬂexibilitywithrespecttothemeansandorderof
assembly by which they are formulated. Two distinct orders
of assembly (“post-PEGylation” versus “pre-PEGylation”)
can be employed. For post-PEGylation, CAL101 is combined
with siRNA to form polyplexes to which PEG-containing
species (i.e., AD-PEG and AD-PEG-Tf) are subsequently
added. By contrast, a pre-PEGylation approach involves
combining all three delivery system components together
to yield a mixture which is then added to siRNA. Both
strategies can provide nanoparticles <100nm in diameter
that demonstrate resistance to salt-induced aggregation.
Because it involves a single mixing step to create nanopar-
ticles at the time of use, the pre-PEGylation strategy was
employed for the nanoparticle investigations described in
the remainder of this paper. In addition, because of nearly
instantaneous nanoparticle formation with this approach
and reproducibility with respect to physicochemical prop-
erties, subsequent investigation of these siRNA-containing
nanoparticles involved formulation at the time of use—that
is, rather than prepare a large quantity of nanoparticles
in advance and store them, separate preparations of (i)
combined delivery components and (ii) siRNA were pro-
vided which were mixed to yielded nanoparticles on theJournal of Drug Delivery 11
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Figure 8: Eﬀect of AD-PEG-Tf incorporation on nanoparticle size,
salt stability, and transgene eﬃciency. (a) Dynamic light scattering
(DLS) measurements of nanoparticle size as a function of time
after the addition of salt (phosphate-buﬀered saline) help to deﬁne
an optimal formulation window above which excessive AD-PEG-
Tf leads to salt-induced nanoparticles aggregation. Nanoparticles
were prepared containing 0% (Ad-PEG) or the indicated mol%
of AD-PEG-Tf (percentage of total cyclodextrins by mole, with
the remaining balance to 100% comprised of AD-PEG). (b) When
plasmid-containing nanoparticles are exposed to cultured cells,
inclusion of AD-PEG-Tf in the formulation increases transgene
expression in a manner that can be reversed by addition of
soluble Tf as a competitor, suggesting that TfR-mediated endo-
cytosis plays a role in nanoparticle uptake and/or intracellular
traﬃcking.Treatmentsincludedcellalone(cells),non-AD-PEG-Tf-
containing nanoparticles (PEG-part.), non-AD-PEG-Tf-containing
nanoparticles plus 0.05mol% free soluble Tf (PEG-part. +Tf), AD-
PEG-Tf-containing nanoparticles (Tf-PEG-part.), non-AD-PEG-
Tf-containing nanoparticles plus 10 equivalents of free soluble Tf
(PEG-part. +Tf+10x Tf), or AD-PEG-Tf-containing nanoparticles
plus10equivalentsoffreesolubleTf(Tf-PEG-part.+10x Tf)(from
[22]).
day of administration. This approach eliminated the need
to demonstrate long-term nanoparticle storage stability and,
owing to a single mixing step, permitted a facile preparation
protocoltowhichitwaseasyforpersonnelatanimalfacilities
and hospital/clinic pharmacies to adhere.
6 .R O N D ELP r oo fo fC o nc e ptin
Tumor-BearingMice:ExpandedNanoparticle
Characterization
Having developed small-scale synthetic procedures for the
three aforementioned components of the delivery system
(CAL101,AD-PEG,andAD-PEG-Tf),anappropriate invivo
model was sought for a proof-of-concept investigation of the
ability of this system to deliver siRNA to tumor cells in mice.
In collaboration with Dr. Timothy Triche and colleagues
at Children’s Hospital Los Angeles, a disseminated murine
model of Ewing’s family of tumors (EFT)—mesenchymal
malignancies that arise in bone or soft tissue or present
as primitive neuroendocrine tumors and typically aﬀect
teenagers—was identiﬁed and selected. The vast major-
ity (85%) of EFT patients have a unique chromosomal
translocation that results in the creation of a chimeric
EWS-Fli1 fusion that serves as an oncogenic transcription
factor. Accordingly, siRNA species targeted speciﬁcally to
the region of fusion had been described [32] which could
induce apoptosis of EFT cells. A potent published anti-EWS-
Fli1 siRNA was utilized within Tf-targeted nanoparticles
to investigate the eﬀect of treatment on cumulative tumor
burden in mice. To create a disseminated EFT model in
mice for which tumor burden could be readily measured,
systemic (tail vein) injections were made of EFT cells which
constitutively expressed ﬁreﬂy luciferase; this allowed the use
ofwhole-animalbioluminescenceimagingtoquantifytumor
burden. Employing a twice-weekly dosing regimen for four
weeks, a statistically signiﬁcant reduction in tumor burden
was observed only for those nanoparticles which contained
(i) the anti-EWS-Fli1 siRNA and (ii) the Tf targeting ligand
(Figure 9(a)). Importantly, this was achieved in the absence
of strong indications of toxicity or immunogenicity in these
animals (Figure 9(b)). Together, these ﬁndings suggested a
strong potential for continued development of this platform
of siRNA-containing nanoparticles as anticancer therapeu-
tics.
Even as these proof-of-concept results were obtained
and Calando Pharmaceuticals was established (in 2005) to
continue development of therapeutic candidates, research
into the fundamental nature and behavior of these siRNA-
containing nanoparticles continued in the laboratory of
Mark Davis at Caltech. Two important publications in 2007
provided a more comprehensive physicochemical and in
vitro biological characterization of these nanoparticles [36]
and examined their biodistribution and pharmacokinetics in
mice [41], respectively. A summary of the characterization
ﬁndings is provided in Table 5. Notably, a combination
of multiple experimental methods, including multiangle
laser light scattering (MALS), allowed determination of
nanoparticle stoichiometry—a 70nm nanoparticle contains
an average of ∼10,000 CAL101 molecules, ∼4000 AD-PEG
molecules, ∼100 AD-PEG-Tf molecules, and ∼2,000 siRNA
molecules. In addition, it was shown that the net ratio of
positive (from CAL101) to negative (from siRNA) charges
in the nanoparticles is ∼1, implying that all additional
CAL101 in the formulation remains as “free” (non-nano-
particle-contained).Sinceitisfreecomponentsthatarelikely12 Journal of Drug Delivery
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Figure 9: RONDEL-based nanoparticles containing siRNA against EWS/Fli-1 were well tolerated by mice and eﬃcacious in a disseminated
murine model of Ewing’s sarcoma. (a) When administered twice weekly for four weeks, only nanoparticles containing AD-PEG-Tf and anti-
EWS/Fli-1 siRNA (D) were eﬀective in reducing tumor burden, as measured as integrated bioluminescence. Treatment group deﬁnitions:
(A): vehicle control (D5W, 5wt% dextrose in water), (B): anti-EWS-Fli1 siRNA without any other nanoparticle components (Naked
siEFBP2), (C): nontargeting siRNA within Tf-targeted nanoparticles (Targ. form siCON#1), (D): anti-EWS-Fli1 siRNA within Tf-targeted
nanoparticles (Targ. form siEFBP2), (E): anti-EWS-Fli1 siRNA within non-Tf-targeted nanoparticles (Nontarg. form siEFBP2). (b) When
administered once to immunocompetent mice, these nanoparticles were well tolerated with respect to liver enzymes (aspartate transaminase
(AST),alaninetransaminase(ALT),alkalinephosphatase(ALKP),platelets(PLTs),indicatorsofkidneyfunction(bloodureanitrogen(BUN)
and creatinine (CRE)), and cytokine response (IL-12(p40) and IFN-α). Wild type denotes untreated mice; all other results are indicated by
treatment group letter (A–E), as deﬁned above, and the time point (2 or 24, in hours) at which blood was sampled (from [23]).Journal of Drug Delivery 13
Table 5: Selected physicochemical properties of siRNA-containing, RONDEL-based nanoparticles.
Property Method Result
Size (diameter) Dynamic light scattering 60 to 150nm
Zeta potential (surface charge) Electrophoretic mobility 0 to +30mV
Nanoparticle molar mass Multiangle laser light scattering (MALS) ∼7e7 to ∼1e9g/mol
Stoichiometry (of 70nm nanoparticle) Various, including MALS
CAL101: ∼10,000 molecules/particle
AD-PEG: ∼4,000 molecules/particle
AD-PEG-Tf: ∼100 molecules/particle
siRNA: ∼2,000 molecules/particle
Table 6: Manufacturers of primary toxicology and initial clinical
lots of CALAA-01 components.
Component Toxicology lot(s) Initial clinical lot(s)
CAL101 Cambrex Cambrex/Agilent
Technologies
AD-PEG Sun Bio Sun Bio
AD-PEG-Tf Calando Pharmaceuticals Agilent Technologies
C05C (siRNA) Agilent Technologies Agilent Technologies
Fill/Finish University of Iowa
Pharmaceuticals
University of Iowa
Pharmaceuticals
responsible for toxicity seen as high nanoparticles doses in
animals (as discussed below), this ﬁnding suggests a strategy
for potentially improving the therapeutic window of these
formulations via removal/reduction in the levels of free
components. To further examine the in vivo properties of
these nanoparticles, positron emission tomography (PET)/
computerized tomography (CT) was employed to monitor
whole-body biodistribution kinetics and tumor localization
of nanoparticles while concurrently using bioluminescence
imaging to measure the ability of the nanoparticles (which
contained antiluciferase siRNA) to downregulate their target
in luciferase-expressing tumors. Comparing Tf-containing
(targeted) versus non-Tf-containing (nontargeted) analogue
formulations, it was revealed that both formulations exhib-
ited similar biodistribution and tumor localization as mea-
sured by PET; however, compartmental modeling showed
that a primary advantage of targeted nanoparticles was
associated with processes involved in cellular uptake by
tumor cells, rather than overall tumor accumulation. Thus,
as has been discussed before [40], the term “internalization
ligand” might well replace “targeting ligand” to describe
the role of Tf in these nanoparticles. In addition, as had
been shown in the EFT work described above, only targeted
nanoparticles in this study were able to achieve a signiﬁcant
reduction in the expression level of the gene target in tumor
cells.
7.RONDEL Translation:Calando
Pharmaceuticals andCALAA-01
Founded in 2005, Calando Pharmaceuticals’ mission is to
develop drug delivery solutions to unlock the promise of
RNAi therapeutics. The company designated the nanoparti-
cle delivery system comprised of the cyclodextrin-containing
polycationandadamantane-basedstabilizationandinternal-
ization components as its RONDEL platform. In addition to
focusing on further advancing the analytical methodologies
andmanufacturingcapabilities(asdiscussedbelow)forthese
components, Calando made substantial eﬀort in the early
days to identify an initial cancer gene target suitable for
eventual clinical application and to optimize an siRNA to
downregulatethattarget.CalandoselectedtheM2subunitof
ribonucleotide reductase (RRM2), an established anticancer
target which catalyzes a rate-limiting step in the produc-
tion of 2 -deoxyribonucleoside 5 -triphosphates which are
necessary for DNA replication. Just as TfR overexpression
across a variety of cancer types opened the possibility of
RONDEL-based nanoparticles to achieve uptake in many
diﬀerent classes of tumors, the demonstrated sensitivity of
manycelltypestoRRM2inhibitionmaintainedthepotential
generality of anti-RRM2 siRNA-containing nanoparticles
to treat multiple types of cancers. A combination of in
silico and in vitro screening of many siRNA candidates led
to identiﬁcation of a lead sequence (named “C05C”; also
referredtoas“siRRM2B+5”)whichwasshowntobeapotent
downregulator of RRM2 in cancer cells of various types and
species and induced a concomitant antiproliferative eﬀect in
those cells [24].
Having deﬁned the four components of Calando’s puta-
tive lead candidate formulation (CAL101, AD-PEG5000, AD-
PEG5000-Tf, and C05C), named “CALAA-01,” campaigns
to scale up the manufacturing of each component were
made while simultaneously expanding and improving the
analytical methods employed to characterize each of them.
The manufacturers of the lots of components used for IND-
enabling toxicology studies and initial clinical material are
listed in Table 6. Improvements in scale of up to three
orders of magnitude were achieved for these molecules,
and, as is customary for such projects, several challenges
were identiﬁed and overcome during development. For
example, in the case of CAL101, a previously unidentiﬁed
impurity created in the initial β-CD functionalization step
was observed that could be carried through subsequent
steps; methodologies for quantifying and removing this
species were developed and employed. Ultimately, suﬃcient
quantities of all components were obtained that satisﬁed
all acceptance criteria and were employed for subsequent
testing.14 Journal of Drug Delivery
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Figure10:Interimdatafromaﬁrst-in-man,phaseIclinicalevaluationofCALAA-01revealsRRM2downregulationviaanRNAimechanism
of action. (a) Measurements of RRM2 mRNA or protein levels in tumor biopsies from three patients (A, B, and C2) obtained before or
after CALAA-01 treatment reveal signiﬁcant reductions in target expression levels. (b) 5 -RLM-RACE analysis of RNA from one patient
(C2) reveals evidence of the precise RRM2 mRNA cleavage product expected from RNAi-mediated down-regulation from the C05C siRNA
contained within CALAA-01. This was the ﬁrst such evidence of the RNAi mechanism of action in humans of any kind (from [26]).
Preclinical safety and eﬃcacy testing of CALAA-01 were
performed across a number of species and tumor types,
respectively. A dose-range-ﬁnding study in non human
primates [25] provided an early glimpse of the safety proﬁle
at each of three diﬀerent dose levels (3, 9, and 27mg/kg
with respect to C05C). Several key ﬁndings were made in
this study, including (i) the nature of toxicity at the highest
dose levels (elevations in blood urea nitrogen and creatinine,
as well as mild transient elevations in transaminase levels,
indicative of kidney and liver eﬀects, resp.), (ii) induc-
tion of mild levels of antinanoparticle (speciﬁcally, anti-
Tf) antibodies that did not aﬀect pharmacokinetics, (iii)
elevationinIL-6atthehighest(27mg/kg)doselevel,and(iv)
identiﬁcation of relatively fast nanoparticle clearance from
circulation (t1/2 < 30min). Importantly, the overall safety
proﬁle indicated good tolerability at the 3 and 9mg/kg dose
levels, in the range for which antitumor eﬀects had been
observed. Additional (unpublished), more comprehensiveJournal of Drug Delivery 15
toxicology and safety-pharmacology studies were performed
in four species (mouse, rat, dog, and nonhuman primate)
which provided a foundation for an initial clinical dose level
and anticipated toxicities. In terms of eﬃcacy, a twice-weekly
dosing regimen of CALAA-01 yielded a signiﬁcant reduction
in tumor burden in mouse subcutaneous tumor models,
includingliverandmelanoma[42],atdoselevelsintherange
of 2.5–10mg/kg.
CALAA-01 preclinical evaluation culminated in the sub-
mission of an Investigational New Drug (IND) application
which received approval in April 2008. Shortly thereafter,
a ﬁrst-in-humans phase I investigation of CALAA-01 in
patients having solid tumors was initiated. Patients who
were refractory to standard-of-care treatment received four
twice-weekly infusions (days 1, 3, 8, and 10) during a 21-
day cycle over which numerous safety evaluations were
made.CTassessmentsoftumorburdenwereperformed,and
PET assessment of tumor metabolism was also made. For
volunteers willing to provide biopsies, assessments of RRM2
levels and investigation of the RNAi mechanism of action
were also performed. At the time of this writing, a phase
Ib study remains open, but interim clinical data have been
published [26, 27]. Several dose level escalations spanning an
order of magnitude (3, 9, 18, 24, and 30mg/m2)h a v eb e e n
tolerated, and key observations of RRM2 downregulation
have been made in multiple patients. Pharmacokinetics
indicate relatively fast clearance, consistent with preclinical
ﬁndings, and some transient elevations in cytokines (IL-6,
IL-10, and TNF-α) were seen. Importantly, the ﬁrst evidence
of the RNAi mechanism in humans (for any siRNA) and
the ﬁrst evidence of dose-dependent tumor accumulation of
nanoparticles administered systemically in humans (for any
nanoparticles) have been observed in this study (Figure 10).
Taken together, these early indications of safety and eﬃcacy
suggest potential for CALAA-01 and the RONDEL platform
for continued clinical investigation.
8. RONDEL and CALAA-01: FutureDirections
Supported by over a decade of research and development,
there are many ongoing and future directions for CALAA-
01 and the RONDEL delivery platform. Certainly com-
pletion of the CALAA-01 phase I clinical trial, including
establishment of a maximum tolerated dose (MTD) and
recommended dose level for subsequent trials, is a near-
term priority. Thorough evaluation of all of the safety
and preliminary eﬃcacy indications from this study will
greatly inform the design of a phase II investigation of
CALAA-01. Beyond CALAA-01, investigation of additional
therapeuticcandidatesemployingtheRONDELsystem,such
as those targeting hypoxia-inducible factor-2α (HIF-2α),
has been undertaken. The relatively fast clearance of these
nanoparticles that has been observed, as has been described
above, suggests that strategies to prolong circulation in
an eﬀort to enhance tumor accumulation may warrant
investigation. The transient elevations in some cytokine
levels seen in interim CALAA-01 clinical data imply that
exploration of chemical modiﬁcations to the siRNA payload
may yield nucleic acids that enhance the nanoparticles
therapeutic index. With encouraging interim clinical data in
hand, avenues for continued development and improvement
of nanoparticles identiﬁed, and the emergence of alternative
siRNA-containing nanoparticles in the clinic from which
all in this ﬁeld will learn, the future for siRNA-containing
nanoparticles based on cyclodextrin-containing polycations
appears bright.
9. Conclusions
CDP-based nanoparticles have made the transition from
the laboratory to the clinic within the last several years.
Two technology platforms have been developed, Cyclosert
for small molecule delivery and RONDEL for nucleic acid
delivery. Both programs have produced a clinical candidate
for oncology, CRLX101 (formerly IT-101), a camptothecin
analog, and CALAA-01, an siRNA therapeutic targeting
RRM2. While clinical development is still in the early phases,
proof of concept was achieved for both technologies. Clinical
development is ongoing and it will be interesting to see what
patient beneﬁts these innovative drugs can provide.
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